The most groundbreaking individual studies from the latest supplement and nutrition research — in plain language, with the evidence caveats built in. Research signals worth knowing about, not health advice.
This large effect comes from a single meta-analysis within a broader umbrella review, and because this is among the first indexed studies on this specific outcome, the result is promising but still preliminary.
This systematic review is the first solid evidence linking vitamin B3 (nicotinamide) to fewer skin cancers, but with only two trials behind it, the finding is promising yet far from settled — especially since the exact dose that works remains unclear.
This review challenges the popular idea that stacking beta-alanine with creatine boosts performance further, but because it’s among the first to analyze this specific pairing, the picture isn’t settled — especially since beta-alanine may still help in narrow, task-specific scenarios not captured here.
This is the first randomized controlled trial to show that turmeric can lower thioredoxin-binding protein-2 (TBP2) and a key inflammatory driver (NF-κB) in people with type 2 diabetes. Because it’s a single study in a clinical population with undisclosed funding, the results are a promising lead — not a settled recommendation.
This is the first broad synthesis to look specifically at vitamin C plus thiamine combinations in sepsis, and the null result means the routine use of this pairing is not supported by current evidence — but because this is an early umbrella review, the picture could shift with better-designed trials.
This is a large effect on symptom severity, but it comes from early-stage, likely unblinded studies, and the benefit does not extend to preventing radiation injury from happening in the first place — so the practical takeaway is narrower than the headline number suggests.
This is the first solid randomized evidence that crocin, a compound from gardenia, might protect the heart during anthracycline chemotherapy, but it’s a single early study in a very specific clinical population — so the finding needs replication before you can trust it for anyone else.
This review challenges the popular belief that turmeric helps muscle recovery, but the evidence is still too sparse and low-quality to draw firm conclusions—especially since this is among the first indexed reviews on the topic.
This single, well-designed trial contradicts the popular idea that high-dose vitamin C is universally protective, but the evidence base is still very weak — only one of four studies on organ dysfunction showed harm, and the rest found no effect, so the picture is far from settled.
This adds to a moderate body of evidence (8 of 9 studies show benefit) that lavender can reduce anxiety, but the effect is seen here in a specific clinical population, and the same study found no improvement in depression or cognitive function — so the benefit is narrower than the headline might suggest.
This is promising early data that ginseng may modestly improve how well blood vessels dilate, but with just one small meta-analysis on this specific question, the finding needs replication before it can be treated as reliable.
This is one of the first indexed reviews to specifically test polyphenols for MS, and it found no signal for EGCG on MRI changes, disability scores, or relapse rates. But the studies it pooled were small and had methodological flaws, so the result is preliminary, not definitive.
This null result challenges the popular belief that astaxanthin boosts male fertility, but because this is among the first indexed meta-analyses on the topic, the evidence is still too thin to consider the question settled.
This is an early, well-designed study suggesting that gut bacteria may help manage oxidative damage after cancer surgery, but because it's among the first of its kind and limited to post-surgery CRC patients, the results can't yet be generalized to healthy people or other conditions.
This is among the first controlled studies to test Bifidobacterium lactis UABla-12 for constipation, but because the probiotic was a multi-strain formula, the specific contribution of that single strain remains unclear — treat this as early, not conclusive, evidence.
This is among the first systematic reviews on sesame oil for blood lipids and glycemic control, but the inconsistent results and narrow focus on diabetic and dyslipidemic patients mean the evidence is still too preliminary to apply broadly.
This is one of the first meta-analyses to systematically assess ginger's anti-inflammatory effects, and the moderate CRP reduction is promising — but without knowing the dose or duration used in the underlying trials, it's hard to translate this into practical advice yet.
This is the strongest signal yet from a small clinical trial that vitamin C can meaningfully reduce oxidative stress in a specific, vulnerable group, but the overall evidence across four studies is only moderate and mixed in effect size, so don't expect this magnitude in a healthy person.
This is one of the first controlled tests of injected vitamin D3 for keloids, so the results are intriguing but far from ready for clinic — the study was small, unblinded, and the benefit may depend on combining treatments rather than vitamin D alone.
This single small study in hospitalized children suggests injected B12 might work faster than oral for severe deficiency, but the evidence is far too thin to change how you or your doctor think about B12 supplementation for the general population.
This is an intriguing signal from a small meta-analysis (509 participants, only 3 studies) where the overall evidence strength is still rated low, so the impressive drop in inflammation should be treated as a promising hypothesis, not a settled fact.
This is the first meta-analysis to suggest vitamin E may protect kidney function during drug injury, but because it’s an early finding with unspecified doses, it’s a clue to watch, not a reason to supplement.
This is an early, small clinical trial suggesting a novel use for vitamin D in orthodontics, but the benefit was narrow (only one measure of relapse improved) and the approach (injected locally, not taken orally) doesn't translate to a supplement you can buy — so treat it as a curiosity, not a takeaway.
This is an unusually large improvement in a key liver enzyme, but the finding comes from a single, moderately-sized clinical trial in a specific patient group, so it doesn't yet tell us whether healthy people or those with milder liver issues would see anything similar.
This is the first solid clinical trial linking milk thistle (as part of a mix) to lower alkaline phosphatase, but the combination product means we don't know how much thistle contributed — and the overall evidence for thistle alone on this marker is still modest and based on small effects.
This meta-analysis of 689 people with fatty liver disease found a moderate, consistent drop in AST (a marker of liver stress), but the benefit stopped there — inflammatory markers and fibrosis scores didn't budge, and the evidence rests on only four studies, so the picture is promising but far from settled.
This is one of the first rigorous trials on this specific probiotic pairing, so the results are promising but far from settled — the real-world impact depends on whether the combination, not just BB-12, drives the effect, and other measures like overall microbiome composition didn't change.
This is one of the first rigorous trials to show that a specific Lactobacillus strain can prevent BV recurrence, but the incomplete effect and novelty mean it's not yet a proven solution for everyone.
This study suggests saw palmetto may have a role as an add-on therapy for men already taking alfuzosin for enlarged prostate symptoms, but it doesn't change the overall weak evidence for saw palmetto as a standalone treatment — and the trial's design (unclear blinding and funding) means the result should be weighed cautiously.
This is the first controlled trial linking Streptococcus thermophilus iHA318 to dry eye relief, so while the results are promising, they come from a small, single study that needs independent confirmation before you can count on it.